Rendering

Component: (Network and Table)
Network
136 - Disclosure - Stockholders' Equity (Tables)
(http://www.dermasciences.com/role/StockholdersEquityTables)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0000892160 (http://www.sec.gov/CIK)
Stockholders' Equity Note [Abstract]Period [Axis]
2015-01-01 - 2015-12-31
Stockholders' Equity Note [Abstract]
 
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
At December 31, 2015, the Company had warrants outstanding to purchase shares of the Company’s common stock consisting of the following:
 
Series
 
Number of Warrants
 
Exercise Price
 
Expiration Date
 
 
 
 
 
 
 
 
 
 
 
R
 
 
1,705,330
 
$
9.90
 
June 22, 2016
 
S
 
 
50,000
 
$
11.81
 
January 14, 2019
 
Total
 
 
1,755,330
 
 
 
 
 
 
  
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]
For the years ended December 31, 2015, 2014 and 2013, the fair value of each option award was estimated at the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions for the years ended December 31, 2015, 2014 and 2013 were as follows:
 
 
 
2015
 
2014
 
2013
 
 
 
 
 
 
 
 
 
 
 
 
Risk-free interest rate
 
 
1.63
%
 
1.79
%
 
1.22
%
Volatility factor
 
 
46.1
%
 
63.2
%
 
69.9
%
Dividend yield
 
 
0
%
 
0
%
 
0
%
Expected option life (years)
 
 
5.81
 
 
5.79
 
 
6.14
 
  
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
A summary of the Company’s stock option activity and related information for the years ended December 31, 2015, 2014 and 2013 follows:
 
 
 
Options
 
Weighted
Average
Exercise Price
 
Weighted
Average
Remaining
Contractual Life
 
 
 
 
 
 
 
 
 
 
 
 
Outstanding – January 1, 2013
 
 
1,639,985
 
$
6.38
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Granted
 
 
421,480
 
$
12.14
 
 
 
 
Forfeited
 
 
(36,878)
 
$
10.99
 
 
 
 
Exercised
 
 
(184,824)
 
$
5.50
 
 
 
 
Expired
 
 
(25,530)
 
$
13.16
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outstanding – December 31, 2013
 
 
1,814,233
 
$
7.67
 
 
6.4 years
 
 
 
 
 
 
 
 
 
 
 
 
Granted
 
 
637,383
 
$
12.98
 
 
 
 
Forfeited
 
 
(116,765)
 
$
12.48
 
 
 
 
Exercised
 
 
(145,053)
 
$
6.42
 
 
 
 
Expired
 
 
(22,839)
 
$
10.70
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outstanding – December 31, 2014
 
 
2,166,959
 
$
9.03
 
 
6.5 years
 
 
 
 
 
 
 
 
 
 
 
 
Granted
 
 
609,090
 
$
8.54
 
 
 
 
Forfeited
 
 
(280,302)
 
$
9.96
 
 
 
 
Exercised
 
 
(129,018)
 
$
4.19
 
 
 
 
Expired
 
 
(64,969)
 
$
9.87
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outstanding – December 31, 2015
 
 
2,301,760
 
$
9.04
 
 
6.5 years
 
 
 
 
 
 
 
 
 
 
 
 
Exercisable at December 31, 2015
 
 
1,855,931
 
$
8.65
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expected to vest at December 31, 2015
 
 
2,278,742
 
$
9.07
 
 
 
 
  
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
During the years ended December 31, 2015, 2014, and 2013 stock option compensation expense was recorded as follows:
 
 
 
2015
 
2014
 
2013
 
 
 
 
 
 
 
 
 
 
 
 
Cost of sales
 
$
168,800
 
$
178,899
 
$
95,726
 
Selling, general and administrative expenses
 
 
2,004,268
 
 
2,625,129
 
 
2,087,827
 
Discontinued operations
 
 
37,397
 
 
194,427
 
 
165,581
 
 
 
 
 
 
 
 
 
 
 
 
Total stock option compensation expense
 
$
2,210,465
 
$
2,998,455
 
$
2,349,134
 
  
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]
The following table summarizes the restricted share unit activity for the years ended December 31, 2015, 2014 and 2013:
 
 
 
Number of
Units
 
Weighted
Average Fair
Value
 
Unvested – January 1, 2013
 
 
786,900
 
$
8.78
 
 
 
 
 
 
 
 
 
Granted
 
 
79,300
 
$
13.65
 
Vested
 
 
(145,650)
 
$
10.18
 
 
 
 
 
 
 
 
 
Unvested – December 31, 2013
 
 
720,550
 
$
9.03
 
 
 
 
 
 
 
 
 
Granted
 
 
101,100
 
$
10.05
 
Vested
 
 
(148,050)
 
$
11.86
 
Cancelled
 
 
(21,717)
 
$
12.78
 
 
 
 
 
 
 
 
 
Unvested – December 31, 2014
 
 
651,883
 
$
8.47
 
 
 
 
 
 
 
 
 
Granted
 
 
124,500
 
$
7.39
 
Vested
 
 
(185,038)
 
$
10.43
 
Cancelled
 
 
(438,595)
 
$
7.30
 
 
 
 
 
 
 
 
 
Unvested – December 31, 2015
 
 
152,750
 
$
8.59
 
  
Schedule Of Common Stock Shares Reserved For Issuance And Shares Available For Grant [Table Text Block]
At December 31, 2015, the Company had reserved the following shares of common stock for future issuance:
 
Convertible preferred shares (Series A – B)
 
73,332
 
Additional stock issuable related to conversion of
  preferred stock
 
49,782
 
Common stock options outstanding
 
2,301,760
 
Common stock warrants outstanding
 
1,755,330
 
Restricted share units outstanding
 
152,750
 
Common stock equivalents available for grant
 
2,420,248
 
Total common stock shares reserved
 
6,753,202